ZVSA ZyVersa Therapeutics, Inc.
Healthcare$0.20+11.00%ClosedMarket Cap: $1.6M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.10
P/S
0.00
EV/EBITDA
-36.93
DCF Value
$0.02
FCF Yield
-284192.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
27.4%
ROA
-244.7%
ROIC
-16.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-1.3M | $-1.79B | $— | — |
| Q4 null | $0.00 | NaN% | $4.18B | $-678.6K | $— | — |
| FY null | $0.00 | NaN% | $-6.8M | $-24.95B | $— | — |
| Q3 null | $0.00 | NaN% | $-2.1M | $-19.8M | $— | — |
| Q2 null | $0.00 | NaN% | $-2.04B | $-2.2M | $— | — |
| Q1 null | $0.00 | NaN% | $-2.14B | $-2.3M | $— | — |
| Q4 null | $26.1K | 50.0% | $-1.3M | $-1.4M | $— | — |
| FY null | $0.00 | -Infinity% | $-9.14B | $-9.41B | $— | — |
| Q3 null | $0.00 | -Infinity% | $-2.3M | $-2.4M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-2.8M | $-2.8M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-2.8M | $-2.8M | $— | — |
| Q4 2023 | $15.6K | 83.3% | $-1.8M | $-13.3M | $-32.92 | — |